Key Takeaways
- Eli Lilly’s triple-hormone receptor drug retatrutide successfully completed its initial Phase 3 trial in individuals with Type 2 diabetes
- The drug achieved HbA1c reductions ranging from 1.7% to 2%, compared to a 0.8% decrease with placebo over 40 weeks
- Trial participants experienced body weight reductions reaching 16.8% on the maximum dosage
- Unlike current treatments targeting one or two hormones, retatrutide activates three pathways (GLP-1, GIP, and glucagon)
- FDA approval has not been submitted; Lilly anticipates data from seven additional Phase 3 studies by late 2025
Eli Lilly revealed Thursday that its investigational medication retatrutide successfully achieved its primary endpoint in its inaugural late-stage diabetes study, demonstrating significant improvements in glycemic control alongside substantial weight reduction in Type 2 diabetes patients.
The clinical study spanned 40 weeks and enrolled Type 2 diabetes patients who were controlling their disease solely through lifestyle modifications—diet and physical activity. Study participants began the trial with baseline HbA1c measurements between 7% and 9.5%.
Across different dosing levels, retatrutide produced average HbA1c decreases between 1.7% and 2%, significantly outperforming the placebo group’s 0.8% reduction. This outcome successfully fulfilled the study’s primary efficacy measure.
Regarding body composition changes, participants receiving the maximum dose experienced an average weight reduction of 16.8% among those who completed treatment. When analyzing the entire study population—including participants who discontinued therapy—the average weight loss stood at 15.3%.
By comparison, Lilly’s currently marketed medication Zepbound produced weight reductions between 11% and 13.1% in similar 40-week studies with diabetes patients. Retatrutide’s performance appears superior, though direct comparison studies have not been conducted.
Louise Chen, an analyst at Scotiabank, characterized these findings as “the highest levels of weight loss we’ve seen from an obesity drug to date” within a population that typically faces challenges achieving significant weight reduction.
Analysts from J.P. Morgan presented a more cautious perspective, observing that the drug’s efficacy gains must be weighed against elevated adverse event frequencies compared to Lilly’s diabetes medication Mounjaro.
Retatrutide’s Mechanism of Action
Retatrutide functions as a once-weekly injectable therapy that stimulates three distinct hormone receptors—GLP-1, GIP, and glucagon—which has led to its “triple-G” designation. This represents one additional receptor compared to Zepbound (tirzepatide), which engages GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which activates only GLP-1.
The therapeutic strategy involves simultaneously targeting all three biological pathways to reduce appetite, regulate glucose metabolism, and enhance metabolic rate.
Adverse reactions predominantly involved the gastrointestinal system. Approximately 26.5% of participants receiving the highest dose experienced nausea, 22.8% reported diarrhea, and 17.6% had vomiting. Treatment discontinuation due to adverse effects reached a maximum of 5%, which Lilly characterized as comparatively modest.
A limited number of participants reported dysesthesia—an abnormal and uncomfortable nerve sensation.
Regulatory Timeline and Next Steps
Lilly has not yet submitted regulatory applications for retatrutide approval in either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 data release for this compound.
The pharmaceutical company anticipates results from seven more Phase 3 clinical trials before year-end 2025, examining various patient demographics and treatment scenarios.
Lilly is simultaneously preparing for the Q2 2025 market introduction of orforglipron, its oral obesity medication, subject to FDA clearance.
Meanwhile, Novo Nordisk is pursuing its own triple-receptor strategy. In March 2025, Novo acquired rights to a triple-receptor candidate from United Laboratories International for up to $2 billion—though this therapy remains in preliminary development stages and requires several years before potential commercialization.
Shares of Lily (LLY) declined modestly in premarket trading Thursday following the trial results announcement.
